Logo
x

Search

Subscribe Now

Taysha Gene Therapies

Taysha Gene Therapies’ TSHA-102 Receives the US FDA’s Regenerative Medicine Advanced Therapy Designation for Rett Syndrome

Taysha Gene Therapies’ TSHA-102 Receives the US FDA’s Regenerative Medicine Advanced Therapy Designation for Rett Syndrome

  • May 3, 2024
Taysha Gene Therapies Reports to Discontinue its TSHA-120 Program in Giant Axonal Neuropathy

Taysha Gene Therapies Reports to Discontinue its TSHA-120 Program in Giant Axonal Neuropathy

  • September 21, 2023
Taysha Gene Therapies’ TSHA-102 Receives the US FDA’s Fast Track Designation for Rett Syndrome

Taysha Gene Therapies’ TSHA-102 Receives the US FDA’s Fast Track Designation for Rett Syndrome

  • August 25, 2023
Taysha Gene Therapies' TSHA-101 Receives the US FDA's Orphan Drug Designation and Rare Pediatric Disease Designation for GM2 Gangliosidosis

Taysha Gene Therapies' TSHA-101 Receives the US FDA's Orphan Drug Designation and Rare Pediatric Disease Designation for GM2 Gangl...

  • August 28, 2020
PharmaShots Weekly Snapshot (Aug 17 -21 2020)

PharmaShots Weekly Snapshot (Aug 17 -21 2020)

  • August 21, 2020
Abeona Signs a License and Inventory Purchase Agreements with Taysha for ABO-202 to Treat CLN1 Disease (Infantile Batten disease)

Abeona Signs a License and Inventory Purchase Agreements with Taysha for ABO-202 to Treat CLN1 Disease (Infantile Batten disease)

  • August 17, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.